C1q activators constitute a diverse array of chemical entities that are characterized by their ability to enhance the functional activity of the C1q protein, a key component of the classical complement pathway. C1q is primarily recognized for its role in the immune system where it binds to the Fc region of antibodies that are attached to pathogens, triggering a series of immune responses that include the opsonization of pathogens and the initiation of a complement cascade resulting in the formation of a membrane attack complex. Activators of C1q can operate through various mechanisms, with some directly binding to the C1q molecule itself, thereby stabilizing its conformation and enhancing its ability to initiate the complement cascade. Others may work by upregulating the cellular pathways that lead to the expression and stabilization of C1q or its receptor interactions, which are essential for its proper functioning in the immune response. These chemicals, while diverse in structure, share the common feature of promoting the activity of C1q without necessarily increasing its expression.
The biochemical activation mechanisms of C1q activators can be quite intricate. Some activators may influence the configuration of C1q, facilitating its interaction with the C1r2s2 complex, which is a crucial step in the activation of the classical pathway. Other compounds may interact with various regulators of complement activation, such as C1 inhibitor (C1-INH), to sustain a favorable balance that promotes C1q function. By influencing the proteases that cleave and activate downstream components of the complement system, such as C4 and C2, these activators indirectly bolster the function of C1q. Although they do not directly modify the protein structure of C1q, their actions on related molecules and signaling pathways result in a net increase in the functional potential of C1q, thus enhancing its role in the immune system's defense mechanisms. Collectively, these activators work in concert to ensure that C1q can effectively fulfill its role in the recognition and clearance of pathogens, as well as in the removal of apoptotic cells, thereby maintaining homeostasis within the immune system.
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | ¥1467.00 ¥3046.00 | 37 | |
组蛋白去乙酰化酶抑制剂可能会改变 C1q 表达的表观遗传调控,从而可能导致其活性发生变化。 | ||||||
MCC950 sodium salt | 256373-96-3 | sc-505904 sc-505904A sc-505904B sc-505904C | 5 mg 10 mg 50 mg 100 mg | ¥1264.00 ¥2189.00 ¥9827.00 ¥17352.00 | 3 | |
MCC950 等化合物可抑制 NLRP3 炎性体,这可能会对包括 C1q 在内的补体激活产生下游影响。 | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | ¥688.00 ¥936.00 ¥3937.00 | 155 | |
BAY 11-7082 等抑制 NF-kB 的化合物可能会影响补体系统基因(包括 C1q)的转录物。 | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | ¥1331.00 ¥3610.00 ¥7017.00 ¥10470.00 ¥13922.00 | 38 | |
PPARγ 激动剂可调节巨噬细胞的功能,从而可能间接影响 C1q 的活性。 | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | ¥361.00 ¥846.00 ¥1331.00 | 14 | |
磷脂酰肌苷-1-磷酸受体调节剂可能会影响淋巴细胞的排出和功能,并对 C1q 活性产生潜在的下游影响。 | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | ¥903.00 ¥2392.00 ¥4603.00 | 48 | |
SB431542 和其他 TGF-β 通路抑制剂可能会影响补体成分(包括 C1q)的表达。 | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | ¥3452.00 | 1 | |
抑制 IKK 的化合物可能会影响 NF-kB 信号,从而影响 C1q 的表达。 |